Back to top

Novo Nordisk announces FDA approval of Rybelsus

Novo Nordisk (NVO) announced that the U.S. FDA has approved Rybelsus, the only oral GLP-1 medication available, for reducing the risk of major adve...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NOV Inc. (NOV)

Novo Nordisk A/S (NVO)